On August 2, an analyst has provided a rating update for the Healthcare company, Aphria Inc (TSXV: APH). The company received a Buy on August 2 from Clarus’ analyst Noel Atkinson.
Atkinson has an average return of 197.6% when recommending Aphria Inc.
According to TipRanks.com, Atkinson is ranked #104 out of 4849 analysts.
Read also: Here’s Why Bellerophon’s (BLPH) Stock Collapsed Today
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aphria Inc with a C$24.50 average price target, a 141.9% upside from current levels. In a report issued on August 1, Canaccord Genuity also maintained a Buy rating on the stock with a C$24.50 price target.
.
Aphria, Inc. engages in the production and supply of medical marijuana. Its products include alien dawg, champlian indica, grower’s blend, champlain-sativa and blueberry. The company was founded by Cole Cacciavillani and John Cervini on June 22, 2011 and is headquartered in Leamington, Canada.
The company’s shares closed on Tuesday at C$10.13.
